Caduet, the ARB+Statin drug, keeps its indisputable position at the top while Hanmi and Daewoong are chasing

It is known that Pfizer’s Caduet has kept its position at the top in the ARB+Statin drug market, representing hypertension+hyperlipidemia complexes. Then, it is followed by other last movers, such as Hanmi Pharm and Daewoong Pharmaceutical.

Caduet (atorvastatin and amlodipine), the first hypertension+hyperlipidemia complex, was launched in Korea on March 2006. Since 7 years after the launch, H...